Celsion Corp. (CLSN) shares are surging by nearly 21% to $3.21 after the company announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in recurrent chest wall (RCW) breast cancer.
Dr. Nicholas Borys, Celsion’s Senior Vice President and Chief Medical Officer said in a statement, “The objective tumor response data including 5 complete responses emerging from the Phase 2 DIGNITY study are extremely impressive, particularly since the patients in the trial presented with highly resistant chest wall tumors that had progressed on multiple therapies, including chemotherapy, radiation and hormone therapy. Together with the data from earlier Phase 1 studies, these interim results highlight the significant potential of ThermoDox® plus hyperthermia to stabilize disease in this difficult-to-treat patient population, and we look forward to bringing this trial to completion later this year.”
CLSN shares recently gained $0.56 to $3.22. In the past 52 weeks, shares of Lawrenceville, New Jersey-based oncology drug development company have traded between a low of $2.15 and a high of $3.73. Shares are up 5.60% year-over-year and 37.34% year-to-date.